LEARN ABOUT OUR BOARD MEMBERS
We are a team of dedicated professionals, ready to do what ever it takes to make Quantapore’s technology a huge success
Dr. Mirko Scherer is responsible for TVM Capital Life Sciences’ fund operations in Greater China. Dr. Scherer joined TVM Capital in early 2015 as a Managing Partner. He is responsible for the China BioPharma Capital I fund’s activities and investments in Europe as well as the United States.
Before joining TVM Capital, Dr. Scherer worked for 2.5 years at the US Venture Capital firm MPM Capital’s Munich office. Before he co-founded GPC Biotech (Munich & Princeton) and served for over a decade as its CFO. In this capacity he was responsible for raising in excess of EUR 350 million via venture capital rounds, IPO (Frankfurt Stock Exchange), secondary listing (Nasdaq) and PIPE investments. He also led the financial, legal, and structuring aspects of numerous M&A and licensing transactions. At the beginning of his professional career Dr. Scherer worked as a management consultant at the Boston Consulting Group (BCG) where he gained experience in banking and utilities industry. His projects included change management, post M&A integration work, and business strategy.
Dr. Scherer completed his doctorate at the European Business School (EBS) in Oestrich Winkel (near Frankfurt/Germany). He earned an MBA from the Harvard Business School in Boston. His MBA studies where supported by a scholarship by the German Academic Exchange Service (DAAD).
Dr.Huber is a co-founder of Quantapore and the inventor of Quantapore’s sequencing technology. Martin holds an M.S. and a Ph.D. in Genetics and Biochemistry (cum laude) from the University of Vienna, Austria. He has over 20 years of experience in biotechnology start-ups both in Europe and the US. During this time he held positions of increasing responsibilities and was involved in the product development process from early feasibility experiments to successful product launches.
Dr. Dennstedt is a co-founder of Quantapore and responsible for business planning and development efforts as well as managing early-stage operations. Dr. Dennstedt is an experienced entrepreneur and has successfully invested in multiple Biotech start-ups as well as in other commercial enterprises.
Mr. Stalfort is a Partner at PBM Capital Group, a private investment group focused on life sciences and health care companies with innovative products that can change the world and improve the quality of people’s lives.
Since 2010, PBM has made several investments relating to next-generation sequencing including Gen9, Genometry, and Firefly BioWorks. Mr. Stalfort also was a founding investor in Enzymatics, a leading producer of reagents, kits and next-generation sequencing assays.
Before PBM Capital, Mr. Stalfort was an Executive Vice President at PBM Products, the word’s leading infant nutrition company, where he directed M&A and New Business Development until the company’s sale to Perrigo for over $800 million. Prior to PBM Products, Mr. Stalfort worked at several private equity, financing and investment banking firms including CS First Boston and Greenwich Capital Markets in various capacities participating in transactions totaling over $4 billion.
Mr. Stalfort earned his B.A. in Business Economics and Political Science from Brown University.